Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

This study has been terminated.

Sponsor:

Collaborator:

National Cancer Institute (NCI)

Information provided by:

Fred Hutchinson Cancer Research Center

ClinicalTrials.gov Identifier:

NCT00673153

First received: May 6, 2008

Last updated: November 3, 2011

Last verified: November 2011

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been terminated.
Estimated Study Completion Date:	No date given
Primary Completion Date:	August 2010 (Final data collection date for primary outcome measure)

No publications provided by Fred Hutchinson Cancer Research Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica. 2012 May;97(5):739-42. Epub 2011 Dec 1.

To Top